IRIS
IAFFALDANO, PIETRO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 5.877
AS - Asia 2.568
EU - Europa 2.030
SA - Sud America 652
AF - Africa 218
OC - Oceania 10
Continente sconosciuto - Info sul continente non disponibili 6
Totale 11.361
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.757
SG - Singapore 988
CN - Cina 586
BR - Brasile 487
IT - Italia 434
SE - Svezia 351
RU - Federazione Russa 326
HK - Hong Kong 319
VN - Vietnam 214
GB - Regno Unito 189
DE - Germania 183
FR - Francia 172
CI - Costa d'Avorio 114
FI - Finlandia 109
IN - India 80
AR - Argentina 74
CA - Canada 64
NL - Olanda 55
BD - Bangladesh 50
JP - Giappone 49
IQ - Iraq 40
UA - Ucraina 40
ID - Indonesia 35
BE - Belgio 33
MX - Messico 33
SA - Arabia Saudita 32
ZA - Sudafrica 27
PL - Polonia 26
EC - Ecuador 24
PK - Pakistan 24
TR - Turchia 24
UZ - Uzbekistan 23
PH - Filippine 22
AT - Austria 21
CO - Colombia 21
ES - Italia 20
VE - Venezuela 19
TN - Tunisia 15
EG - Egitto 11
JO - Giordania 11
KE - Kenya 11
LT - Lituania 11
CL - Cile 10
MA - Marocco 9
MY - Malesia 9
AE - Emirati Arabi Uniti 8
AU - Australia 8
CZ - Repubblica Ceca 8
IL - Israele 8
IE - Irlanda 7
PY - Paraguay 7
ET - Etiopia 6
IR - Iran 6
NP - Nepal 6
PT - Portogallo 6
AL - Albania 5
RO - Romania 5
SN - Senegal 5
UY - Uruguay 5
CR - Costa Rica 4
DZ - Algeria 4
EE - Estonia 4
HU - Ungheria 4
JM - Giamaica 4
KG - Kirghizistan 4
KZ - Kazakistan 4
LB - Libano 4
PS - Palestinian Territory 4
AZ - Azerbaigian 3
BB - Barbados 3
BG - Bulgaria 3
BO - Bolivia 3
CH - Svizzera 3
DK - Danimarca 3
DO - Repubblica Dominicana 3
EU - Europa 3
LV - Lettonia 3
MZ - Mozambico 3
OM - Oman 3
PA - Panama 3
A1 - Anonimo 2
MK - Macedonia 2
NZ - Nuova Zelanda 2
RW - Ruanda 2
TH - Thailandia 2
AM - Armenia 1
AO - Angola 1
BF - Burkina Faso 1
BJ - Benin 1
BT - Bhutan 1
BY - Bielorussia 1
GA - Gabon 1
GE - Georgia 1
GH - Ghana 1
GL - Groenlandia 1
GM - Gambi 1
GR - Grecia 1
GT - Guatemala 1
HN - Honduras 1
HR - Croazia 1
Totale 11.339
Salva come PNG Salva come JPEG
Città #
Ashburn 673
Fairfield 616
Singapore 507
Chandler 431
Woodbridge 378
Hong Kong 319
Dallas 313
San Jose 287
Houston 274
Nyköping 270
Seattle 254
Ann Arbor 240
Cambridge 211
Beijing 175
Wilmington 175
Abidjan 114
Los Angeles 102
Lauterbourg 99
New York 84
Lawrence 80
Jacksonville 77
Roxbury 71
Bari 69
Helsinki 69
Ho Chi Minh City 67
Brooklyn 56
São Paulo 54
Des Moines 49
Boardman 47
Council Bluffs 47
Tokyo 44
Chicago 42
Munich 42
Hanoi 41
Nanjing 41
Buffalo 39
Princeton 37
Santa Clara 37
London 36
Moscow 36
Frankfurt am Main 35
Brussels 33
Amsterdam 32
Falkenstein 31
Nuremberg 31
Orem 31
Inglewood 30
Toronto 28
San Diego 27
Guangzhou 26
North Bergen 26
Jakarta 20
Paris 20
Norwalk 19
Salt Lake City 18
Warsaw 18
Milan 17
Rio de Janeiro 17
Shanghai 17
Atlanta 16
Johannesburg 16
Montreal 16
Poplar 15
Baghdad 14
Jeddah 14
Rome 14
Tashkent 14
Dong Ket 13
Stockholm 13
Tianjin 13
Dhaka 12
Bisceglie 11
Chennai 11
Denver 11
Haiphong 11
Lahore 11
Quito 11
San Francisco 11
Shenyang 11
Amman 10
Buenos Aires 10
Manchester 10
Nanchang 10
Phoenix 10
Da Nang 9
Dearborn 9
Nairobi 9
Taranto 9
Vienna 9
Washington 9
Belo Horizonte 8
Boston 8
Cagliari 8
Medellín 8
Naples 8
Riyadh 8
Wuhan 8
Ankara 7
Dublin 7
Hebei 7
Totale 7.518
Salva come PNG Salva come JPEG
Nome #
Correction to: Disability assessment using Google Maps (Neurological Sciences, (2022), 43, 2, (1007-1014), 10.1007/s10072-021-05389-7) 210
Signs and symptoms of COVID-19 in patients with multiple sclerosis 210
RELATIONSHIP OF COGNITIVE PERFORMANCES AND EMPLOYMENT STATUS IN PEOPLE WITH RELAPSING MULTIPLE SCLEROSIS 206
Comparison of switch to fingolimod or interferon beta/glatiramer acetate in active multiple sclerosis 189
Fingolimod versus interferon beta/glatiramer acetate after natalizumab suspension in multiple sclerosis 189
Long-term disability trajectories in relapsing multiple sclerosis patients treated with early intensive or escalation treatment strategies 180
Gender differences in safety issues during Fingolimod therapy: Evidence from a real-life Relapsing Multiple Sclerosis cohort 179
Prognostic indicators in pediatric clinically isolated syndrome 179
Computer-assisted rehabilitation of attention in pediatric multiple sclerosis and ADHD patients: a pilot trial 178
Lymphocyte subsets as biomarkers of therapeutic response in Fingolimod treated Relapsing Multiple Sclerosis patients 177
Retrospectively acquired cohort study to evaluate the long-term impact of two different treatment strategies on disability outcomes in patients with relapsing multiple sclerosis (RE.LO.DI.MS): data from the Italian MS Register 166
Comparative effectiveness of natalizumab and fingolimod treatment on cognitive functions in relapsing multiple sclerosis. ECTRIMS 2016 - Poster Session 2 160
Acute myeloid leukemia in Italian patients with multiple sclerosis treated with mitoxantrone. 155
Lymphocyte count and body mass index as biomarkers of early treatment response in a multiple sclerosis dimethyl fumarate-treated cohort 155
Computer-assisted rehabilitation of attention in patients with multiple sclerosis: results of a randomized, double-blind trial. 152
Country, Sex, EDSS Change and Therapy Choice Independently Predict Treatment Discontinuation in Multiple Sclerosis and Clinically Isolated Syndrome. 149
Load-dependent dysfunction of the putamen during attentional processing in patients with clinically isolated syndrome suggestive of multiple sclerosis. 145
Impact of natalizumab on cognitive performances and fatigue in relapsing multiple sclerosis: a prospective, open-label, two years observational study. 142
SCLEROSI MULTIPLA E LAVORO: DATI PRELIMINARI 142
Multiple sclerosis registries in Europe – An updated mapping survey 141
Verbal fluency deficits in clinically isolated syndrome suggestive of multiple sclerosis. 140
Treatment decisions in multiple sclerosis-insights from real-world observational studies 135
Predictors of long-term disability accrual in relapse-onset multiple sclerosis 132
Sclerosi Multipla e Lavoro: dati preliminari 130
Seroconversion and indolent course of COVID-19 in patients with multiple sclerosis treated with fingolimod and teriflunomide 130
Treating multiple sclerosis with natalizumab. 128
Long-term comparative analysis of no evidence of disease activity (NEDA-3) status between multiple sclerosis patients treated with natalizumab and fingolimod for up to 4 years 127
Multiple Sclerosis Progression and Relapse Activity in Children 123
Detection of disability worsening in relapsing-remitting multiple sclerosis patients. A real-world roving EDSS-Expanded Disability Status Scale reference analysis from the Italian Multiple Sclerosis Register 123
Disease-modifying drugs can reduce disability progression in relapsing multiple sclerosis 122
Long-term follow-up of pediatric MS patients starting treatment with injectable first-line agents: A multicentre, Italian, retrospective, observational study 121
COVID-19 Severity in Multiple Sclerosis: Putting Data Into Context 119
Clinical effectiveness of different natalizumab interval dosing schedules in a large Italian population of patients with multiple sclerosis 116
The role of neutralizing antibodies to interferon-β as a biomarker of persistent MRI activity in multiple sclerosis: a 7-year observational study 115
Safety profile of Tysabri: international risk management plan 114
The frequency of CSF oligoclonal banding in multiple sclerosis increases with latitude. 114
The improvement of cognitive functions is associated with a decrease of plasma Osteopontin levels in Natalizumab treated relapsing multiple sclerosis. 114
DMTs and Covid-19 severity in MS: a pooled analysis from Italy and France 114
Emotional and neutral verbal memory impairment in Multiple Sclerosis 114
Durvalumab and multiple sclerosis: a causal link or simple unmasking? 114
Serum neurofilament light chain levels are increased in patients with a clinically isolated syndrome 112
Risk of multiple sclerosis relapses when switching from fingolimod to cell-depleting agents: the role of washout duration 112
Neuromyelitis optica spectrum disorders associated with systemic sclerosis: a case report and literature review 112
Low serum urate levels are associated to female gender in multiple sclerosis patients. 111
Conversion from clinically isolated syndrome to multiple sclerosis: A large multicentre study 111
Natalizumab discontinuation is associated with a rebound of cognitive impairment in multiple sclerosis patients 110
Longitudinal Evaluation of Serum MOG-IgG and AQP4-IgG Antibodies in NMOSD by a Semiquantitative Ratiometric Method 110
null 109
Serum and CSF N-acetyl aspartate levels differ in multiple sclerosis and neuromyelitis optica 109
Dengue fever in a multiple sclerosis patient taking Ocrelizumab 109
Natural history of multiple sclerosis: have available therapies impacted long-term prognosis? 108
Effect of cladribine on neuronal apoptosis: New insight of in vitro study in multiple sclerosis therapy 108
Real-Life Experience of the Effects of Cladribine Tablets on Lymphocyte Subsets and Serum Neurofilament Light Chain Levels in Relapsing Multiple Sclerosis Patients 105
Postmarketing evidence of disease-modifying drugs in multiple sclerosis 105
First evidence of in vivo pro-angiogenic activity of cerebrospinal fluid samples from multiple sclerosis patients 102
PML risk is the main factor driving the choice of discontinuing natalizumab in a large multiple sclerosis population: results from an Italian multicenter retrospective study 102
Disability assessment using Google Maps 102
Defining the course of tumefactive multiple sclerosis: a large retrospective multicentre study 101
Predictors of unemployment status in people with relapsing multiple sclerosis: a single center experience 101
Clinical and biological predictors of Cladribine effectiveness in Multiple Sclerosis: A real-world, single Centre study considering a two-year interval from year-2 dosing 100
Geographical variations in sex ratio trends over time in multiple sclerosis. 99
Data monitoring roadmap. The experience of the Italian Multiple Sclerosis and Related Disorders Register 97
Predictors and dynamics of postpartum relapses in women with multiple sclerosis. 97
A Randomized Computer-Assisted Rehabilitation Trial of Attention in Pediatric Multiple Sclerosis: A Post Hoc Analysis 96
Impact of depression on the perception of fatigue and information processing speed in a cohort of multiple sclerosis patients 94
Early treatment delays long-term disability accrual in RRMS: Results from the BMSD network 94
Transition to secondary progression in relapsing-onset multiple sclerosis: Definitions and risk factors 93
Post-natalizumab disease reactivation in multiple sclerosis: systematic review and meta-analysis 93
Anxiety state affects information processing speed in patients with multiple sclerosis 85
Disease-modifying therapies in managing disability worsening in paediatric-onset multiple sclerosis: a longitudinal analysis of global and national registries 84
Natalizumab reduces serum pro-angiogenic activity in MS patients 84
Disease-Modifying Treatments and Time to Loss of Ambulatory Function in Patients With Primary Progressive Multiple Sclerosis 82
A comparison of natalizumab and ocrelizumab on disease progression in multiple sclerosis 81
Effectiveness of fingolimod in real-world relapsing-remitting multiple sclerosis Italian patients: the GENIUS study 81
Assessing long-term effectiveness of MS treatment - a matter of debate 81
Treatment Switching and Discontinuation Over 20 Years in the Big Multiple Sclerosis Data Network 77
Big Multiple Sclerosis Data network: an international registry research network 75
Progression independent of relapse activity in relapsing multiple sclerosis: impact and relationship with secondary progression 73
null 73
Risk of Persistent Disability in Patients With Pediatric-Onset Multiple Sclerosis 73
The impact of neutralizing antibodies on the risk of disease worsening in interferon β-treated relapsing multiple sclerosis: a 5 year post-marketing study. 72
Active and non-active secondary progressive multiple sclerosis patients exhibit similar disability progression: results of an Italian MS registry study (ASPERA) 70
Risk of Getting COVID-19 in People With Multiple Sclerosis 70
SARS-CoV-2 serology after COVID-19 in multiple sclerosis: An international cohort study 69
null 68
null 67
Disease-Modifying Therapies and Coronavirus Disease 2019 Severity in Multiple Sclerosis 67
Serum N-acetyl-aspartate in Relapsing Remitting Multiple Sclerosis 65
null 65
Towards a validated definition of the clinical transition to secondary progressive multiple sclerosis: A study from the Italian MS Register 65
Evaluation of drivers of treatment switch in relapsing multiple sclerosis: a study from the Italian MS Registry 64
Long-term follow-up of pediatric MS patients starting treatment with injectable first-line agents: A multicentre, Italian, retrospective, observational study 64
Siponimod from fingolimod direct switch in patients transitioning in secondary progressive multiple sclerosis: A single center case series 63
Interdisciplinary approach to opportunistic infections: staphylococcal meningitis in a patient with multiple sclerosis on treatment with dimethyl fumarate 62
Disability trajectories by progression independent of relapse activity status differ in pediatric, adult and late-onset multiple sclerosis 61
The effect of air pollution on COVID-19 severity in a sample of patients with multiple sclerosis 61
Real-life impact of early interferonbeta therapy in relapsing multiple sclerosis 60
Progression is independent of relapse activity in early multiple sclerosis: a real-life cohort study 59
Serum N-acetyl aspartate (NAA) levels differ in multiple sclerosis (MS) and neuromyelitis optica (NMO). 58
null 56
Totale 10.986
Salva come PNG Salva come JPEG
Categoria #
all - tutte 50.278
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 50.278
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021279 0 0 0 0 0 0 0 0 0 109 90 80
2021/2022754 61 72 21 23 49 87 34 44 51 48 117 147
2022/20231.102 158 170 88 87 128 131 20 120 151 4 26 19
2023/2024442 41 54 29 24 41 95 16 25 6 30 11 70
2024/20252.094 149 38 126 74 68 153 223 187 126 116 291 543
2025/20264.557 653 362 478 473 540 381 447 192 545 486 0 0
Totale 11.797